PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
 
J Psychiatry Neurosci. 1997 July; 22(4): 235–243.
PMCID: PMC1188864

The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia.

Abstract

The purpose of the present study was to examine the relationship between neurocognitive deficits and self-reported quality of life in order to examine whether neurocognitive impairment interferes with any aspects of quality of life for patients with schizophrenia. Forty-two outpatients with stable chronic schizophrenia were assessed for neurocognitive deficits using a computerized test battery, and all patients completed a version of the Sickness Impact Profile (SIP) to assess their quality of life across a variety of domains. The neurocognitive assessment tests revealed significant deficits compared with normal control subjects, particularly with respect to impaired iconic memory and frontal functioning. Patients reported that their quality of life was compromised. Despite the substantiation of marked neurocognitive deficits and reduced quality of life, correlations between neurocognitive deficits and quality of life were largely nonsignificant or very weak. Symptom expression, however, particularly with regard to general psychopathology on the Positive and Negative Syndrome Scale (PANSS), was significantly associated with quality of life. These results suggest that neurocognitive deficits in schizophrenia, while often profound, appear to have little direct impact on the patient's perceived quality of life.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry. 1992 Mar;43(3):262–265. [PubMed]
  • Balogh DW, Merritt RD. Visual masking and the schizophrenia spectrum: interfacing clinical and experimental methods. Schizophr Bull. 1987;13(4):679–698. [PubMed]
  • Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981 Aug;19(8):787–805. [PubMed]
  • Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull. 1992;28(4):353–366. [PubMed]
  • Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am. 1993 Jun;16(2):295–312. [PubMed]
  • Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996 Mar;153(3):321–330. [PubMed]
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. [PubMed]
  • Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988 Jan;23(1):99–110. [PubMed]
  • Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989 Nov;(7):59–67. [PubMed]
  • Lehman AF, Ward NC, Linn LS. Chronic mental patients: the quality of life issue. Am J Psychiatry. 1982 Oct;139(10):1271–1276. [PubMed]
  • Neale JM. Perceptual span in schizophrenia. J Abnorm Psychol. 1971 Apr;77(2):196–204. [PubMed]
  • Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull. 1984;10(2):160–203. [PubMed]
  • Orzack MH, Kornetsky C. Environmental and familial predictors of attention behavior in chronic schizophrenics. J Psychiatr Res. 1971 Dec;9(1):21–29. [PubMed]
  • Rund BR. Backward-masking performance in chronic and nonchronic schizophrenics, affectively disturbed patients, and normal control subjects. J Abnorm Psychol. 1993 Feb;102(1):74–81. [PubMed]
  • Rund BR, Landrø NI. Information processing: a new model for understanding cognitive disturbances in psychiatric patients. Acta Psychiatr Scand. 1990 Apr;81(4):305–316. [PubMed]
  • Saccuzzo DP, Braff DL. Early information processing deficit in schizophrenia. New findings using schizophrenic subgroups and manic control subjects. Arch Gen Psychiatry. 1981 Feb;38(2):175–179. [PubMed]
  • Schuck JR, Lee RG. Backward masking, information processing, and schizophrenia. Schizophr Bull. 1989;15(3):491–500. [PubMed]
  • Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia. 1975 Aug 21;43(2):103–113. [PubMed]
  • Spaulding W, Garbin CP, Dras SR. Cognitive abnormalities in schizophrenic patients and schizotypal college students. J Nerv Ment Dis. 1989 Dec;177(12):717–728. [PubMed]
  • Stanovich KE, Purcell DG. Comment on "Input capability and speed of processing in mental retardation" by Saccuzzo, Kerr, Marcus and Brown. J Abnorm Psychol. 1981 Apr;90(2):168–171. [PubMed]
  • Wyatt RJ. Biochemistry and schizophrenia (part IV) the neuroleptics--their mechanism of action: a review of the biochemical literature. Psychopharmacol Bull. 1976 Jul;12(3):5–50. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association